+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Nuclear Medicine Market - Global Forecast 2026-2032- Product Image
Nuclear Medicine Market - Global Forecast 2026-2032- Product Image
Sale

Nuclear Medicine Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5206422
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Nuclear Medicine Market is projected to reach USD 13.93 Billion in 2026. It is expected to continue growing at a CAGR of 9.36%, reaching USD 23.88 Billion by 2032.

Nuclear medicine is moving from a primarily diagnostic specialty toward an integrated precision medicine platform that combines PET/CT, SPECT/CT, radiopharmaceutical therapy, companion diagnostics, and patient-specific dosimetry. The field benefits from strong clinical demand in oncology, cardiology, neurology, endocrinology, and infection imaging, with technetium-99m remaining the workhorse for SPECT and fluorine-18, gallium-68, copper-64, zirconium-89, iodine-131, lutetium-177, and actinium-225 supporting higher-value diagnostic and therapeutic use cases.

Verified public health data reinforces the long-term need for nuclear medicine services. The WHO/IARC GLOBOCAN 2022 database reported about 20 million new cancer cases and 9.7 million cancer deaths worldwide, while WHO estimates more than 55 million people live with dementia globally. Cardiovascular disease also remains the leading cause of death worldwide, according to WHO, supporting sustained demand for myocardial perfusion imaging, molecular imaging, radiotracer development, targeted radionuclide therapy, and scalable radiopharmacy infrastructure.

Transformative Shifts in the Nuclear Medicine Landscape

The most important shift in the nuclear medicine landscape is the rise of theranostics, where the same biological target is used for diagnosis, patient selection, therapy, and response monitoring. FDA approvals such as lutetium Lu-177 dotatate for somatostatin receptor-positive neuroendocrine tumors and lutetium Lu-177 vipivotide tetraxetan for PSMA-positive prostate cancer have validated clinical and commercial models for targeted radiopharmaceutical therapy.

At the same time, supply chain resilience has become a strategic priority. Molybdenum-99 and technetium-99m availability depends on a limited global production network, while short half-life PET isotopes require localized cyclotron, generator, or distribution capacity. Hospitals, radiopharmacies, and manufacturers are therefore investing in generator networks, automated synthesis, quality control systems, cold-kit innovation, workforce training, and regional isotope production to reduce disruption risk and improve patient access.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is compounding the value of nuclear medicine by improving image reconstruction, attenuation correction, lesion detection, organ segmentation, quantitative PET/SPECT analysis, and workflow prioritization. The FDA public list of AI/ML-enabled medical devices includes hundreds of cleared products, with radiology representing the largest category, demonstrating regulatory acceptance of algorithm-supported imaging workflows.

In nuclear medicine, AI is especially relevant because quantitative accuracy directly affects staging, therapy selection, and dosimetry. AI-enabled tools can reduce scan time, support low-dose protocols, harmonize multi-center trial data, assist PSMA and somatostatin receptor lesion assessment, and automate absorbed-dose calculations for radionuclide therapy. The cumulative impact is a shift from visual interpretation toward reproducible, data-rich molecular imaging that supports precision oncology, clinical trial efficiency, and value-based care.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

North America remains a leading nuclear medicine region due to advanced PET/CT adoption, a strong FDA pathway for radiopharmaceutical approvals, established reimbursement for many nuclear imaging procedures, and active clinical trial networks in prostate cancer, neuroendocrine tumors, cardiology, and neurology. Europe combines mature hospital infrastructure with EMA oversight, European Association of Nuclear Medicine clinical guidance, and strong radiopharmaceutical research, while European Union cross-border regulatory coordination and isotope initiatives support standardization and supply security.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in cancer centers, cyclotrons, PET/CT capacity, and domestic isotope capabilities to address rising oncology, cardiovascular, and neurological disease burdens. Latin America, led by Brazil and Mexico, shows rising demand but faces uneven access to cyclotrons, radiopharmacies, trained specialists, and reimbursement. The Middle East is building specialized oncology and diagnostic imaging capacity through hospital modernization programs, particularly in GCC countries, while Africa remains underpenetrated, with IAEA support, national cancer control initiatives, and public-sector hospital investment playing important roles in expanding access to radiopharmaceutical services.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

The G7 countries anchor a large share of high-value nuclear medicine adoption because they combine advanced hospital infrastructure, regulatory capacity, isotope production expertise, academic trial networks, and reimbursement systems that support PET/CT, SPECT/CT, and radiopharmaceutical therapy. NATO markets overlap significantly with North American and European healthcare systems, where nuclear medicine supports military, veteran, and civilian healthcare through oncology imaging, cardiac perfusion imaging, bone scintigraphy, and infection evaluation.

The European Union is central to radiopharmaceutical regulation, research funding, clinical standardization, and medical isotope supply security discussions. BRICS countries are becoming increasingly important because Brazil, Russia, India, China, and South Africa represent large patient populations, nuclear science capabilities, and rising oncology investment. ASEAN countries are improving PET/CT and SPECT access as urban tertiary care expands, while the GCC is investing in premium hospital infrastructure, cancer care, advanced diagnostic imaging, and regional radiopharmacy capabilities to reduce dependence on imported services.

Key Country Insights Across Major Nuclear Medicine Markets

The United States leads in radiopharmaceutical innovation, FDA-approved theranostics, PET imaging, and clinical development, while Canada contributes isotope expertise, cyclotron networks, and academic nuclear medicine research. Mexico and Brazil are important Latin American markets where expanding oncology capacity supports PET/CT and SPECT demand. The United Kingdom, Germany, France, Italy, and Spain maintain mature nuclear medicine networks, and Germany and France are particularly influential in radiopharmaceutical research, manufacturing, clinical guidance, and hospital-based adoption.

Russia retains nuclear science and isotope capabilities, while China and India are scaling imaging capacity to meet large cancer and cardiovascular disease burdens. Japan and South Korea combine advanced imaging adoption with strong technology ecosystems, and Australia is notable for theranostics leadership, nuclear medicine training, and regional clinical research. Across the United States, Canada, Mexico, Brazil, the United Kingdom, Germany, France, Russia, Italy, Spain, China, India, Japan, Australia, and South Korea, access depends on reimbursement, isotope logistics, specialist workforce availability, radiation safety infrastructure, and hospital investment in PET/CT, SPECT/CT, cyclotrons, generators, and radiopharmacy systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize theranostic portfolio development, secure isotope sourcing, and differentiated radiopharmaceutical manufacturing capabilities. Partnerships with hospitals, cyclotron operators, generator suppliers, academic centers, and contract development and manufacturing organizations can reduce capacity bottlenecks and accelerate clinical adoption.

Commercial success also requires evidence generation beyond regulatory approval. Organizations should invest in real-world outcomes, health economics, dosimetry validation, AI-enabled quantification, clinician education, multidisciplinary tumor boards, and patient referral pathways. Building resilient cold-chain logistics, automated quality control, radiation safety programs, and reimbursement dossiers will be essential for scaling nuclear medicine from specialized centers to broader oncology and diagnostic networks.

Research Methodology

This executive summary is built from publicly verifiable secondary research and cross-validated industry intelligence. Core sources include WHO, IARC GLOBOCAN, IAEA, OECD, FDA, EMA, EANM, SNMMI, national health agencies, peer-reviewed clinical literature, regulatory approval databases, and publicly available institutional disclosures.

The methodology applies triangulation across disease burden, procedure demand, isotope availability, radiopharmaceutical approvals, technology adoption, reimbursement conditions, and regional infrastructure. Market interpretation focuses on verified indicators rather than unsupported estimates, with emphasis on clinical utility, supply chain feasibility, regulatory pathways, radiation safety, and commercialization readiness across nuclear medicine diagnostics and therapeutics.

Conclusion

Nuclear medicine is entering a high-value clinical growth phase driven by precision oncology, theranostics, AI-enabled imaging, and the need for earlier, more accurate disease characterization. Clinical validation of PSMA-targeted and somatostatin receptor-targeted radiopharmaceuticals has shifted the sector from niche imaging toward integrated diagnosis, therapy selection, and response monitoring.

The strongest opportunities will favor organizations that can combine scientific credibility, isotope security, manufacturing quality, data-driven workflows, radiation safety, and regional market access. As cancer, cardiovascular disease, and neurodegenerative disorders continue to create global healthcare pressure, nuclear medicine is positioned to become a core pillar of personalized diagnosis, treatment planning, and long-term patient management.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Nuclear Medicine Market, by Product Type
7.1. Introduction
7.2. Diagnostic Radiopharmaceuticals
7.2.1. Positron Emission Tomography (PET) Isotopes
7.2.2. Single Photon Emission Computed Tomography (SPECT) Isotopes
7.3. Therapeutic Nuclear Medicine
7.3.1. Brachytherapy Isotopes
7.3.1.1. Cesium-131
7.3.1.2. Iodine-125
7.3.1.3. Iridium-192
7.3.1.4. Palladium-103
7.3.2. Radiopharmaceutical Therapy
7.3.2.1. Alpha Emitters
7.3.2.2. Beta Emitters
8. Nuclear Medicine Market, by Mode Of Administration
8.1. Introduction
8.2. Intravenous Injection
8.3. Oral Ingestion
9. Nuclear Medicine Market, by Usage
9.1. Introduction
9.2. Diagnostic Procedure
9.2.1. PET Scanners
9.2.1.1. Analog PET
9.2.1.2. Digital PET
9.2.2. SPECT Scanners
9.3. Therapeutic Procedure
10. Nuclear Medicine Market, by Application
10.1. Introduction
10.2. Cardiology
10.3. Endocrinology
10.4. Gastroenterology
10.5. Neurology
10.6. Oncology
10.7. Orthopedics
10.8. Pulmonology
11. Nuclear Medicine Market, by End Users
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Diagnostic Centers
11.4. Hospitals
11.4.1. Government Hospitals
11.4.2. Private Hospitals
12. Nuclear Medicine Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Nuclear Medicine Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Nuclear Medicine Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. 3B Pharmaceuticals GmbH
16.2. Actinium Pharmaceuticals, Inc.
16.3. B J Madan & Co.
16.4. Bayer AG
16.5. Bracco S.p.A.
16.6. BWX Technologies, Inc.
16.7. Clarity Pharmaceuticals
16.8. Curium
16.9. Eli Lilly and Company
16.10. GE HealthCare
16.11. IBA
16.12. Institute of Isotopes Co., Ltd
16.13. Isotopia Molecular Imaging Ltd.
16.14. Jubilant Pharma Limited
16.15. Lantheus Holdings, Inc.
16.16. Medi-Radiopharma Co., Ltd.
16.17. Nordion
16.18. Northstar Medical Technologies LLC
16.19. Novartis AG
16.20. Nusano, Inc.
16.21. PeptiDream Inc.
16.22. Radiopharm Theranostics Limited
16.23. SHINE Technologies, LLC
16.24. Siemens Healthineers AG
16.25. Sinotau Pharmaceuticals Group
16.26. South African Nuclear Energy Corporation
16.27. State Atomic Energy Corporation Rosatom
16.28. Thor Medical AS by Nordic Nanovector ASA
List of Figures
FIGURE 1. GLOBAL NUCLEAR MEDICINE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL NUCLEAR MEDICINE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL NUCLEAR MEDICINE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL NUCLEAR MEDICINE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL NUCLEAR MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL NUCLEAR MEDICINE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL NUCLEAR MEDICINE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL POSITRON EMISSION TOMOGRAPHY (PET) ISOTOPES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) ISOTOPES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL THERAPEUTIC NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CESIUM-131 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CESIUM-131 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CESIUM-131 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL IODINE-125 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL IODINE-125 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IODINE-125 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL IRIDIUM-192 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL IRIDIUM-192 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL IRIDIUM-192 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PALLADIUM-103 MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PALLADIUM-103 MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PALLADIUM-103 MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL BETA EMITTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL BETA EMITTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ORAL INGESTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ORAL INGESTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ORAL INGESTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DIAGNOSTIC PROCEDURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DIAGNOSTIC PROCEDURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DIAGNOSTIC PROCEDURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL PET SCANNERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PET SCANNERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PET SCANNERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ANALOG PET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ANALOG PET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ANALOG PET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL DIGITAL PET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL DIGITAL PET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DIGITAL PET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SPECT SCANNERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SPECT SCANNERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SPECT SCANNERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL THERAPEUTIC PROCEDURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTIC PROCEDURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL THERAPEUTIC PROCEDURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ORTHOPEDICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ORTHOPEDICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ORTHOPEDICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL PULMONOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL PULMONOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PULMONOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL GOVERNMENT HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 118. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 120. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 121. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 122. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 123. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 124. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 128. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 130. EUROPE NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 157. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 160. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 161. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 162. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 163. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 164. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 165. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 166. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 167. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 169. AFRICA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 184. NATO NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. NATO NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 186. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 187. NATO NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 188. NATO NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 189. NATO NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 190. NATO NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 191. NATO NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 192. NATO NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 193. NATO NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 194. NATO NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 195. NATO NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 196. NATO NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 197. G7 NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. G7 NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 199. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 200. G7 NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 201. G7 NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 202. G7 NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 203. G7 NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. G7 NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 205. G7 NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 206. G7 NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 207. G7 NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. G7 NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 209. G7 NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 210. BRICS NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 212. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 213. BRICS NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 214. BRICS NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 215. BRICS NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 216. BRICS NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 217. BRICS NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 218. BRICS NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 219. BRICS NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 220. BRICS NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 221. BRICS NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 222. BRICS NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 228. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 229. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 231. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 232. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 233. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 236. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 237. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 238. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 239. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 240. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 241. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 242. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 244. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 245. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 246. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 247. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 248. ASEAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 249. GCC NUCLEAR MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. GCC NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 251. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 252. GCC NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 253. GCC NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 254. GCC NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 255. GCC NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 256. GCC NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 257. GCC NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 258. GCC NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 259. GCC NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 260. GCC NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 261. GCC NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 262. GLOBAL NUCLEAR MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 263. CHINA NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 264. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 265. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 266. CHINA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 267. CHINA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 268. CHINA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 269. CHINA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 270. CHINA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 271. CHINA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 272. CHINA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 273. CHINA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 274. CHINA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 275. CHINA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 281. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 282. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 284. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 285. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 286. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 289. JAPAN NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 291. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 292. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 293. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 294. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 295. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 297. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 298. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 299. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 300. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 301. JAPAN NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 302. INDIA NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 304. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 305. INDIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 306. INDIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 307. INDIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 308. INDIA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 309. INDIA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 310. INDIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 311. INDIA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 312. INDIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. INDIA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 314. INDIA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 315. GERMANY NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 317. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 318. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 319. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 320. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 321. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 323. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 324. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 325. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 326. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 327. GERMANY NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 333. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 334. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 335. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 336. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 337. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 338. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 339. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 340. UNITED KINGDOM NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 341. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 342. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 343. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 344. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY RADIOPHARMACEUTICAL THERAPY, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY USAGE, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC PROCEDURE, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY PET SCANNERS, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY END USERS, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA NUCLEAR MEDICINE MARKET SIZE, BY HOSPITALS, 2017-2032 (USD MILLION)
TABLE 354. FRANCE NUCLEAR MEDICINE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 356. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY DIAGNOSTIC RADIOPHARMACEUTICALS, 2017-2032 (USD MILLION)
TABLE 357. FRANCE NUCLEAR MEDICINE MARKET SIZE, BY THERAPEUTIC NUCLEAR MEDICINE, 2017-2032 (USD MILLION)
TABLE 358. F

Companies Mentioned

  • 3B Pharmaceuticals GmbH
  • Actinium Pharmaceuticals, Inc.
  • B J Madan & Co.
  • Bayer AG
  • Bracco S.p.A.
  • BWX Technologies, Inc.
  • Clarity Pharmaceuticals
  • Curium
  • Eli Lilly and Company
  • GE HealthCare
  • IBA
  • Institute of Isotopes Co., Ltd
  • Isotopia Molecular Imaging Ltd.
  • Jubilant Pharma Limited
  • Lantheus Holdings, Inc.
  • Medi-Radiopharma Co., Ltd.
  • Nordion
  • Northstar Medical Technologies LLC
  • Novartis AG
  • Nusano, Inc.
  • PeptiDream Inc.
  • Radiopharm Theranostics Limited
  • SHINE Technologies, LLC
  • Siemens Healthineers AG
  • Sinotau Pharmaceuticals Group
  • South African Nuclear Energy Corporation
  • State Atomic Energy Corporation Rosatom
  • Thor Medical AS by Nordic Nanovector ASA

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 13.93 Billion
Forecasted Market Value ( USD ) by 2032 $ 23.88 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Nuclear Medicine & Radiopharmaceuticals Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine & Radiopharmaceuticals Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Nuclear Medicine Market by Type, Application, Procedure, End User, and Region - Global Forecast to 2030 - Product Image

Nuclear Medicine Market by Type, Application, Procedure, End User, and Region - Global Forecast to 2030

  • Report
  • 536 Pages
  • Global
From
Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Nuclear Medicine (Radiopharmaceuticals) - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Report
  • 150 Pages
  • Global
From
Nuclear Medicine Radioisotope - Global Strategic Business Report - Product Image

Nuclear Medicine Radioisotope - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From

About the Nuclear Medicine Market

Nuclear Medicine is a field of medicine that uses radioactive materials to diagnose and treat diseases, particularly cancer. Nuclear Medicine is used to detect and monitor the progression of cancer, as well as to provide targeted treatments. It is used to detect cancer cells in the body, to measure the effectiveness of cancer treatments, and to provide targeted radiation therapy. Nuclear Medicine can also be used to detect and monitor the spread of cancer to other parts of the body. Nuclear Medicine is used in combination with other treatments, such as chemotherapy and surgery, to provide a comprehensive approach to cancer care. It is also used to provide palliative care, to reduce pain and improve quality of life for cancer patients. Nuclear Medicine is a rapidly growing field, with new technologies and treatments being developed to improve the diagnosis and treatment of cancer. Companies in the Nuclear Medicine market include GE Healthcare, Siemens Healthineers, Philips Healthcare, and Toshiba Medical Systems. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.